by Jen Hodson | Nov 7, 2019 | Press Releases
Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety Culver City, Calif., Nov. 7, 2019 – NantKwest Inc. (Nasdaq: NK), a next generation, clinical-stage...
by Jen Hodson | Jun 3, 2019 | Press Releases
CULVER CITY, CA. – June 3, 2019 – ImmunityBio , a privately held immunotherapy company at late stage clinical development, that aims to synergistically deploy a broad portfolio of biological molecules as an integrated cancer vaccine platform targeting multiple...
